Free Trial

10 Best Penny Stocks to Buy Now - 4 of 10

 
 

Immunic (NASDAQ:IMUX)

Number of Upgrades from Top-Ranked Analysts
4 (in the last 90 days)
Consensus Rating
Buy
Rating Score
3.3
Ratings Breakdown
7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$11.80 (1,080.0% Upside)

About Immunic

Immunic logoImmunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
11/25/2024HC WainwrightInitiated CoverageBuy$10.00
9/16/2024EF Hutton Acquisition Co. IUpgradeStrong-Buy
9/9/2024Leerink PartnrsUpgradeStrong-Buy
9/9/2024Leerink PartnersReiterated RatingOutperform$5.00
8/27/2024B. RileyInitiated CoverageBuy$6.00
7/16/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$28.00 ➝ $28.00
4/5/2024Brookline Capital ManagementReiterated RatingBuy$10.00
11/14/2023WedbushReiterated RatingOutperform$7.00
10/10/2023WedbushBoost Price TargetOutperform ➝ Outperform$5.00 ➝ $7.00
8/4/2023WedbushReiterated RatingOutperform$5.00
 

Rare "crisis signal" triggers for third time in U.S. market (Ad)

A rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the market crashed 78% (the dot-com bust) and 89% (the Great Depression). Today, according to one of America's leading experts (who has predicted nearly every financial crisis of the last 25 years), what's coming next could soon crash the market by 50% or more, and keep it down for 10, 20, or even 30 years.

Click here for all the details.